Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Volitionrx (VNRX) EPS (Weighted Average and Diluted) (2023 - 2025)

Volitionrx filings provide 4 years of EPS (Weighted Average and Diluted) readings, the most recent being $0.0 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 104.07% to $0.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $0.0, a 100.79% increase, with the full-year FY2025 number at $0.0, up 100.44% from a year prior.
  • EPS (Weighted Average and Diluted) hit $0.0 in Q4 2025 for Volitionrx, up from -$0.05 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.0 in Q4 2025 to a low of -$0.12 in Q4 2023.
  • Median EPS (Weighted Average and Diluted) over the past 3 years was -$0.06 (2024), compared with a mean of -$0.07.
  • The widest YoY moves for EPS (Weighted Average and Diluted): up 104.07% in 2025, down 25.0% in 2025.
  • Volitionrx's EPS (Weighted Average and Diluted) stood at -$0.12 in 2023, then skyrocketed by 50.86% to -$0.06 in 2024, then soared by 104.07% to $0.0 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were $0.0 (Q4 2025), -$0.05 (Q3 2025), and -$0.06 (Q2 2025) per Business Quant data.